Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC1143 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 13.3 | uM | 7430.085 | 1.0388 | 1.0393 | 1.9592 | |
| HCC1143 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 66.7 | uM | 7430.085 | 0.3615 | 0.1898 | 1.9592 | |
| HCC1143 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 333 | uM | 7430.085 | 0.0127 | -0.7847 | 1.9592 | |
| HCC1187 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00256 | uM | 7432.084 | 1.0837 | 1.1974 | 0.8538 | |
| HCC1187 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0128 | uM | 7432.084 | 1.0873 | 1.2061 | 0.8538 | |
| HCC1187 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.064 | uM | 7432.084 | 1.0923 | 1.2179 | 0.8538 | |
| HCC1187 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.32 | uM | 7432.084 | 1.1190 | 1.2816 | 0.8538 | |
| HCC1187 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1.6 | uM | 7432.084 | 1.1976 | 1.4704 | 0.8538 | |
| HCC1187 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 8 | uM | 7432.084 | 1.0662 | 1.1559 | 0.8538 | |
| HCC1187 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 40 | uM | 7432.084 | 0.6304 | 0.1650 | 0.8538 | |
| HCC1187 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 200 | uM | 7432.084 | 0.4265 | -0.2628 | 0.8538 | |
| HCC1187 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1000 | uM | 7432.084 | 0.1833 | -0.7259 | 0.8538 | |
| HCC1187 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00256 | uM | 7433.084 | 1.0283 | 1.0550 | 1.0291 | |
| HCC1187 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0128 | uM | 7433.084 | 1.0641 | 1.1244 | 1.0291 | |
| HCC1187 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.064 | uM | 7433.084 | 0.9927 | 0.9859 | 1.0291 | |
| HCC1187 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.32 | uM | 7433.084 | 0.9906 | 0.9817 | 1.0291 | |
| HCC1187 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1.6 | uM | 7433.084 | 1.1076 | 1.2089 | 1.0291 | |
| HCC1187 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 8 | uM | 7433.084 | 0.8977 | 0.8010 | 1.0291 | |
| HCC1187 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 40 | uM | 7433.084 | 0.6913 | 0.3972 | 1.0291 | |
| HCC1187 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 200 | uM | 7433.084 | 0.8632 | 0.7337 | 1.0291 | |
| HCC1187 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1000 | uM | 7433.084 | 0.0020 | -0.9953 | 1.0291 | |
| HCC1395 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00256 | uM | 7435.084 | 0.9671 | 0.9241 | 0.8646 | |
| HCC1395 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0128 | uM | 7435.084 | 0.9395 | 0.8607 | 0.8646 | |
| HCC1395 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.064 | uM | 7435.084 | 0.9425 | 0.8675 | 0.8646 | |
| HCC1395 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.32 | uM | 7435.084 | 0.9911 | 0.9794 | 0.8646 |